Royalty Pharma PLC (NASDAQ: RPRX) is a biopharmaceutical royalty company that acquires royalties on approved and late-stage medicines. It makes money by collecting royalty payments tied to the net sales of drugs developed and commercialized by third-party pharmaceutical and biotechnology companies. The filing excerpts provided do not contain sufficient detail to characterize segment revenue, specific royalty assets, geographic mix, capital structure, founding year, or competitive positioning beyond the core royalty acquisition model. Based solely on the available excerpts, no further specifics about products, revenue figures, customer concentration, or management can be confirmed for FY2025.

Revenue model

Royalty payments on net sales of biopharmaceutical products, collected from third-party drug developers and commercializers whose intellectual property rights underlie acquired royalties.

Value-chain role

Capital provider and royalty acquirer in the biopharmaceutical value chain, sitting between drug developers and end-market sales revenue.

Source: SEC 10-K, filed 2026-02-11

Industry: Pharmaceutical Preparations Peers: Bristol-Myers Squibb Co Catalent, Inc. Elanco Animal Health Inc Eli Lilly and Co Johnson & Johnson Merck & Co Inc Organon & Co Pfizer Inc Viatris Inc Zoetis Inc